New Three-Drug cocktail targets Hard-to-Treat lymphoma
NCT ID NCT02992522
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the combination. Researchers will also watch for early signs that the drugs are shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab, venetoclax, and lenalidomide
- What this could lead to
- If it works, this could point toward a new treatment option for patients with B-cell non-Hodgkin lymphoma that has returned or stopped responding to prior therapy.
- What could go wrong
- This is a very early Phase I trial with only 22 participants, so it is primarily testing safety and dosing. The combination may cause significant side effects or may not shrink tumors effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can two immune boosters outsmart follicular lymphoma without chemo?
- Can a Two-Pronged antibody boost chemo against tough lymphomas?
- Triple-Drug cocktail aims to boost remission in follicular lymphoma
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma